INT115927

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 27
Total Number 27
Disease Relevance 4.16
Pain Relevance 4.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Hspg2) extracellular region (Hspg2) proteinaceous extracellular matrix (Hspg2)
extracellular matrix organization (Hspg2)
Anatomy Link Frequency
noses 2
sensory neurons 1
keratinocyte 1
neutrophils 1
Hspg2 (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 42 99.92 Very High Very High Very High
imagery 218 99.88 Very High Very High Very High
antagonist 463 99.74 Very High Very High Very High
Inflammation 60 97.38 Very High Very High Very High
fifth nerve 16 88.28 High High
agonist 61 86.32 High High
cytokine 15 85.60 High High
addiction 21 82.68 Quite High
TRP channel 10 82.48 Quite High
Calcium channel 3 80.68 Quite High
Disease Link Frequency Relevance Heat
Targeted Disruption 225 99.52 Very High Very High Very High
Necrosis 30 99.48 Very High Very High Very High
Bullous Skin Disease 304 98.68 Very High Very High Very High
Nociception 21 98.44 Very High Very High Very High
Acantholysis 65 98.08 Very High Very High Very High
INFLAMMATION 62 97.38 Very High Very High Very High
Stress 61 90.52 High High
Disease 42 89.68 High High
Pruritus 101 83.52 Quite High
Pressure And Volume Under Development 9 82.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Consistent with its ability to inhibit PLC-beta2 enzymatic activity, U73122 reduced interleukin-8 and leukotriene B(4)-induced Ca(2+) flux and chemotaxis in human neutrophils in a concentration-dependent manner.
Negative_regulation (inhibit) of PLC in neutrophils
1) Confidence 0.57 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 14730005 Disease Relevance 0.30 Pain Relevance 0.08
D609, a pharmacological PC-PLC inhibitor, has previously been shown to inhibit SMS activity in vitro [27], [44], [54], and cellular studies showed that SMS activity was inhibited by concentrations used to previously study PC-PLC [43], [44], [55].
Negative_regulation (inhibitor) of PLC
2) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3011003 Disease Relevance 0.08 Pain Relevance 0
To investigate the role of phospholipase C (PLC) in inflammatory processes, we tested 1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122), a widely used PLC inhibitor, in several in vitro and in vivo assays.
Negative_regulation (inhibitor) of PLC associated with inflammation
3) Confidence 0.42 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 14730005 Disease Relevance 0.23 Pain Relevance 0.09
decreased from 15.36 ± 0.34 (sensitized control) to 10.10 ± 0.44 (% mean ± SE) in the PLC-treated group, at 100 mg/kg (p < 0.01).
Negative_regulation (decreased) of PLC
4) Confidence 0.19 Published 2010 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2885635 Disease Relevance 0 Pain Relevance 0.08
The responses were suppressed significantly by a PLC inhibitor, suggesting involvement of the PLC pathway.
Negative_regulation (inhibitor) of PLC
5) Confidence 0.18 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2912856 Disease Relevance 0.15 Pain Relevance 0.09
Further, we determined sensory signaling transduction mechanisms using both TRPM5 knockout mice and inhibitors to block the activity of TRPM5 and PLC.
Negative_regulation (block) of PLC associated with targeted disruption
6) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0.10 Pain Relevance 0
TRPM5 inhibitors Ph3PO (100 µM) and PLC inhibitor U73122 (10 µM) respectively were delivered to the noses of individual animals using the same method described in stimulus delivery.
Negative_regulation (delivered) of PLC in noses
7) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0 Pain Relevance 0.03
Third, the PLC inhibitor U73122 suppresses the stimulus-induced Ca2+ responses in SCCs as well as disrupts the regulation on the access of such chemicals.
Negative_regulation (inhibitor) of PLC
8) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0.20 Pain Relevance 0.08
Similar to the TRPM5 inhibitor, application of the PLC inhibitor U73122 also disrupted the regulation on access to the VNO of bitter compounds in wild type but not in TRPM5 knockout mice.
Negative_regulation (inhibitor) of PLC associated with targeted disruption
9) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0.50 Pain Relevance 0.04
TRPM5 inhibitors Ph3PO (100 µM) and PLC inhibitor U73122 (10 µM) respectively were delivered to the noses of individual animals using the same method described in stimulus delivery.
Negative_regulation (inhibitor) of PLC in noses
10) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0 Pain Relevance 0
The PLC inhibitor U73122 and its inactive analogue U73343 (Calbiochem, San Diego, CA) were dissolved in DMSO and diluted into the bath solution at a final concentration of 5 µM for Ca2+ imaging experiment and 10 µM for the dye assay.
Negative_regulation (inhibitor) of PLC associated with imagery
11) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0 Pain Relevance 0.35
In Ca2+ imaging, the PLC inhibitor U73122 (5 µM), but not the negative control U73343 (5 µM), strongly suppressed the Ca2+ responses induced by denatonium and lilial (t-test, p?
Negative_regulation (inhibitor) of PLC associated with imagery
12) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2912856 Disease Relevance 0 Pain Relevance 0.09
These results clearly demonstrate that the mechanism underlying the progression of the proper sleep sequence is impaired in PLC-?
Negative_regulation (impaired) of PLC
13) Confidence 0.16 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2770323 Disease Relevance 0 Pain Relevance 0
As shown in Fig. 2D, inhibition of PLC using the PLC?
Negative_regulation (inhibition) of PLC
14) Confidence 0.08 Published 2010 Journal Cell Signal Section Body Doc Link PMC2791881 Disease Relevance 0 Pain Relevance 0.26
Because a chelator of intracellular free Ca2+ blocked keratinocyte dissociation in vitro and inhibitors of calmodulin, PLC and PKC were effective to block PV-IgG-induced acantholysis in vivo (Arredondo et al. 2005; Sanchez-Carpintero et al. 2004), it is possible that this signalling pathway may be involved in PV acantholysis.
Negative_regulation (inhibitors) of PLC in keratinocyte associated with kinase c, acantholysis and bullous skin disease
15) Confidence 0.03 Published 2008 Journal Histochem Cell Biol Section Body Doc Link PMC2413110 Disease Relevance 0.82 Pain Relevance 0.20
-induced elevation in COX-2 Luciferase (Fig. 5C) and mRNA expression (Fig. 5D) was significantly inhibited by co-treatment of cells with the FP receptor antagonist (AL8810), and chemical inhibitors of PLC (U73122), PKA (4C3MQ), EGFR kinase (AG1478) and ERK1/2 kinase (PD98059), but not the EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227) or PKC inhibitor (GF109203x; Fig. 5C and D, P < 0.05).


Negative_regulation (inhibitors) of PLC associated with antagonist
16) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.36
We next evaluated the effect of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227) and chemical inhibitors of PLC (U73122), PKC (GF109203x), PKA (4C3MQ), EGFR (AG1478) and ERK1/2 kinase (MEK; PD98059) on the PGE2 or PGF2?
Negative_regulation (inhibitors) of PLC associated with antagonist
17) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.34
The PGE2 (Fig. 6B) -induced activation of CRE Luciferase was significantly reduced by treatment of FPS cells with the FP receptor (AL8810), EP2 receptor (AH6809), or EP4 receptor (ONOAE2227) antagonists or chemical inhibitors of PLC (U73122), PKA (4C3MQ), EGFR kinase (AG1478) or ERK1/2 kinase (PD98059), but not the PKC inhibitor (GF109203x; Fig. 6B P < 0.05).
Negative_regulation (inhibitors) of PLC associated with antagonist
18) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.27
stimulation of FPS cells induces ERK1/2 phosphorylation via identical intracellular signaling pathways via the PLC-PKA-mediated activation of the EGFR since co-treatment of cells with the PLC, PKA or EGFR kinase inhibitors significantly inhibited the PGE2 or PGF2?
Negative_regulation (inhibitors) of PLC
19) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.11
in the presence/absence of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227), or chemical inhibitors of PLC (U73122), PKA (4C3MQ), PKC (GF109203x), EGFR kinase (AG1478) or ERK1/2 kinase (PD98059).
Negative_regulation (inhibitors) of PLC associated with antagonist
20) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.31

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox